Literature DB >> 1131283

Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice.

B H Hahn, L Knotts, M Ng, T R Hamilton.   

Abstract

NZB/NZW mice were treated with various immunosuppressive drugs used in human SLE. Cyclophosphamide (5 mg/kg 6 days out of 7), alone or with prednisolone, was better than azathioprine, prednisolone, or azathioprine-plus-prednisolone, in prolonging survival and/or reducing proteinuria, Coomb's antibodies, antinuclear antibodies, and glomerular deposits of gamma-globulin. Intermittent bolus therapy with cyclophosphamide (59 mg/kg/10 days) was as effective as daily therapy. However, 61% of the mice receiving any cyclophosphamide regimen developed malignant tumors compared to none in the other groups.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1131283     DOI: 10.1002/art.1780180212

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  18 in total

1.  Increased survival times of New Zealand hybrid mice immunosuppressed by graft-versus-host reactions.

Authors:  D H Lehman; C B Wilson; F J Dixon
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

2.  Therapeutic effect of beta-[1-phenyl-5-bis(beta-chloroethyl)-amino-benzimidazolyl-(2)-DL-alanin (ZIMET 3164) on immune complex nephritis of NZB hybrid mice.

Authors:  J Güttner
Journal:  Agents Actions       Date:  1979-12

3.  Antigenic charge as a factor in resistance to immunosuppressive therapy.

Authors:  S G Adler; H Y Wang; A H Cohen; W A Border
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

4.  The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice.

Authors:  E R Hurd; M Ziff
Journal:  Clin Exp Immunol       Date:  1977-07       Impact factor: 4.330

Review 5.  Suppression of autoimmune diseases with anti-idiotypic antibodies: murine lupus nephritis as a model.

Authors:  B H Hahn
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Suppressed hetergeneous antinuclear antibody response in lymphomabearing NZB/NZW mice.

Authors:  S E Walker; G G Bole
Journal:  Clin Exp Immunol       Date:  1976-04       Impact factor: 4.330

7.  The differential effects of cyclophosphamide and 6-mercaptopurine on the renal disease and skin immunoglobulin deposits of the NZB-NZW F1 hybrid mice.

Authors:  E R Hurd; J N Gilliam; M Ziff
Journal:  Agents Actions       Date:  1976-02

8.  A pharmacologic study of the relationship between lymphocyte function and surface antigen expression.

Authors:  M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1988-08

9.  Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice.

Authors:  D Girard; R M Aloisi; M L Bliven; A C Cunningham; I G Otterness
Journal:  Agents Actions       Date:  1990-03

10.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.